Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium, 2013 to 2023. - 2024
Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium, 2013 to 2023.
[en] BackgroundAntimicrobial resistance to mupirocin and fusidic acid, which are used for treatment of skin infections caused by Staphylococcus aureus, is of concern.AimTo investigate resistance to fusidic acid and mupirocin in meticillin-susceptible S. aureus (MSSA) from community-acquired skin and soft tissue infections (SSTIs) in Belgium.MethodsWe collected 2013-2023 data on fusidic acid and mupirocin resistance in SSTI-associated MSSA from two large Belgian laboratories. Resistant MSSA isolates sent to the Belgian Staphylococci Reference Centre were spa-typed and analysed for the presence of the eta and etb virulence genes and the mupA resistance gene. In addition, we whole genome sequenced MSSA isolates collected between October 2021 and September 2023.ResultsMupirocin resistance increased between 2013 and 2023 from 0.5-1.5% to 1.7-5.6%. Between 2018 and 2023, 91.4% (64/70) of mupirocin-resistant isolates were co-resistant to fusidic acid. By September 2023, between 8.9% (15/168) and 10.1% (11/109) of children isolates from the two laboratories were co-resistant. Of the 33 sequenced isolates, 29 were sequence type 121, clonal and more distantly related to the European epidemic fusidic acid-resistant impetigo clone (EEFIC) observed in Belgium in 2020. These isolates carried the mupA and fusB genes conferring resistance to mupirocin and fusidic acid, respectively, and the eta and etb virulence genes.ConclusionWe highlight the spread of a mupirocin-resistant EEFIC in children, with a seasonal trend for the third quarter of the year. This is of concern because this variant is resistant to the two main topical antibiotics used to treat impetigo in Belgium.
Disciplines :
Immunology & infectious disease
Author, co-author :
Yin, Nicolas ; National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium
Michel, Charlotte ; National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium
Makki, Nadia; Department of microbiology, Algemeen Medisch Laboratorium (AML), Antwerp, Belgium
Deplano, Ariane ; National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium
Milis, Alisha; Department of microbiology, Algemeen Medisch Laboratorium (AML), Antwerp, Belgium
Prevost, Benoit; National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium
Miendje-Deyi, Veronique Yvette ; Department of microbiology, LHUB-ULB, Université libre de Bruxelles, Brussels, Belgium
Hallin, Marie ; Centre for environmental health and occupational health, Public health school, Université libre de Bruxelles, Brussels, Belgium ; European Plotkin institute for vaccinology (EPIV), Faculty of medicine, Université libre de Bruxelles, Brussels, Belgium ; These authors contributed equally to the work and share the last authorship
Martiny, Delphine ; Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service du Doyen de la Faculté de Médecine et Pharmacie ; National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium ; These authors contributed equally to the work and share the last authorship
Language :
English
Title :
Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium, 2013 to 2023.
Publication date :
May 2024
Journal title :
Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles
ISSN :
1025-496X
eISSN :
1560-7917
Publisher :
European Centre for Disease Prevention and Control (ECDC), Sweden
O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol. 2007;45(5):1505-10. https://doi.org/10.1128/JCM.01984-06 PMID: 17344365
Rørtveit S, Skutlaberg DH, Langeland N, Rortveit G. The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway. Scand J Infect Dis. 2014;46(12):832-7. https://doi.org/10.3109/00365548.2014.947317 PMID: 25229166
Dalager-Pedersen M, Søgaard M, Schønheyder HC. Staphylococcus aureus skin and soft tissue infections in primary healthcare in Denmark: a 12-year population-based study. Eur J Clin Microbiol Infect Dis. 2011;30(8):951-6. https://doi.org/10.1007/s10096-011-1179-0 PMID: 21279531
Deplano A, Hallin M, Bustos Sierra N, Michel C, Prevost B, Martiny D, et al. Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium. J Antimicrob Chemother. 2023;78(8):2061-5. https://doi.org/10.1093/jac/dkad204 PMID: 37358399
Belgian Antibiotic Policy Coordination Commission (BAPCOC). Guide belge de traitement anti-infectieux en pratique ambulatoire/Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. [Belgian guide for treatment of infections in outpatient practice]. Brussels: BAPCOC; Nov 2022. French/Dutch. Available from: https://organesdeconcertation.sante.belgique.be/fr/documents/guide-belge-de-traitementanti-infectieux-en-pratique-ambulatoire-2022
Nederlands Huisartsen Genootschap (NHG). Bacteriële huidinfecties (M68). [Bacterial skin infections]. Utrecht: NHG; May 2019. Dutch. Available from: https://richtlijnen.nhg.org/files/pdf/61_Bacteri%C3%ABle%20huidinfecties_mei-2019.pdf
Doudoulakakis A, Spiliopoulou I, Spyridis N, Giormezis N, Kopsidas J, Militsopoulou M, et al. Emergence of a Staphylococcus aureus clone resistant to mupirocin and fusidic acid carrying exotoxin genes and causing mainly skin infections. J Clin Microbiol. 2017;55(8):2529-37. https://doi.org/10.1128/JCM.00406-17 PMID: 28592549
Haute autorité de santé (HAS). Prise en charge des infections cutanées bactériennes courantes. [Management of common bacterial skin infections]. Saint-Denis: HAS; Feb 2019. French. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-04/prise_en_charge_des_infections_cutanees_bacteriennes_courantes_recommandations.pdf
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, Jan 2023. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2023_manuals/Manual_v_11.0_EUCAST_Disk_Test_2023.pdf
Loffeld A, Davies P, Lewis A, Moss C. Seasonal occurrence of impetigo: a retrospective 8-year review (1996-2003). Clin Exp Dermatol. 2005;30(5):512-4. https://doi.org/10.1111/j.13652230.2005.01847.x PMID: 16045681
Ramsey MA, Bradley SF, Kauffman CA, Morton TM. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother. 1996;40(12):2820-3. https://doi.org/10.1128/AAC.40.12.2820 PMID: 9124848
Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun. 2002;70(2):631-41. https://doi.org/10.1128/IAI.70.2.631-641.2002 PMID: 11796592
Hallin M, Deplano A, Denis O, De Mendonça R, De Ryck R, Struelens MJ. Validation of pulsed-field gel electrophoresis and spa typing for long-term, nationwide epidemiological surveillance studies of Staphylococcus aureus infections. J Clin Microbiol. 2007;45(1):127-33. https://doi.org/10.1128/JCM.01866-06 PMID: 17093021
Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455-77. https://doi.org/10.1089/cmb.2012.0021 PMID: 22506599
Zhou W, Jin Y, Teng G, Chen W, Chen Y, Luo Q, et al. Comparative analysis of genomic characteristics, virulence and fitness of community-associated Staphylococcus aureus ST121 clone causing fatal diseases in China and other CA-MRSA clones. Virulence. 2023;14(1):2242547. https://doi.org/10.1080/21505594.2023.2242547 PMID: 37534993
Kurt K, Rasigade JP, Laurent F, Goering RV, Žemličková H, Machova I, et al. Subpopulations of Staphylococcus aureus clonal complex 121 are associated with distinct clinical entities. PLoS One. 2013;8(3):e58155. https://doi.org/10.1371/journal.pone.0058155 PMID: 23505464
Lamand V, Dauwalder O, Tristan A, Casalegno JS, Meugnier H, Bes M, et al. Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains. Clin Microbiol Infect. 2012;18(12):E514-21. https://doi.org/10.1111/1469-0691.12053 PMID: 23078129
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;1(1):CD003261. PMID: 22258953
George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480-7. PMID: 12939895
Yang LPH, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68(6):855-73. https://doi.org/10.2165/00003495-200868060-00008 PMID: 18416589
Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, et al. Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial. JAMA Dermatol. 2018;154(7):806-13. https://doi.org/10.1001/jamadermatol.2018.1103 PMID: 29898217
European Medicines Agency (EMA). Medicines. Amsterdam: EMA. [Accessed: 21 Feb 2024]. Available from: https://www.ema.europa.eu/en/medicines
National Institute for Health and Care Excellence (NICE). Impetigo: antimicrobial prescribing. London: NICE; 26 Feb 2020. Available from: https://www.nice.org.uk/guidance/ng153
Van den Wijngaert S, Bossuyt N, Ferns B, Busson L, Serrano G, Wautier M, et al. Bigger and Better? Representativeness of the influenza A surveillance using one consolidated clinical microbiology laboratory data set as compared to the Belgian Sentinel Network of Laboratories. Front Public Health. 2019;7:150. https://doi.org/10.3389/fpubh.2019.00150 PMID: 31275914
Gorges H, Hall L, Heal C. Feasibility study for a randomised controlled trial for the topical treatment of impetigo in Australian general practice. Trop Med Infect Dis. 2021;6(4):197. https://doi.org/10.3390/tropicalmed6040197 PMID: 34842831
